OTC · Financial Statements

Mentari Therapeutics, Inc. (MTRI) Revenue, Earnings & Financial Statements

$19.87 OTC: MTRI Market Cap $10.92M

Data as of Nov 16, 2026 (intraday, delayed) · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Mentari Therapeutics, Inc. most recently reported annual revenue of $5.0M, a net loss of $13.0M. Revenue grew at an average annual rate of 25.7% over the last 4 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Mentari Therapeutics, Inc.: Revenue rose from $2.0M in 2021 to $5.0M in 2025, a change of +150.0% over 4 years; net profit was positive in 0 of 7 reported years; operating margin moved from -536.0% to -192.0%, a shift of +344.0 percentage points; the most recent year shows a net loss of $13.0M.

Income Statement — 7 Years (USD millions)

Metric2020202120222023202420252026
Revenue—$2.0M$1.0M$4.0M$5.0M$5.0M—
Operating Expenses$9.0M$12.0M$20.0M$12.0M$9.0M$8.0M$12.0M
Operating Profit—−$10.0M−$19.0M−$8.0M———
Operating Margin—-536.0%-1707.0%-192.0%———
Other Income$0$0−$1.0M$0$1.0M$1.0M$1.0M
Interest$0$0$0$0$0$0$0
Depreciation$0$0$0$0$0$0$0
Profit Before Tax—−$10.0M−$19.0M−$8.0M−$8.0M−$9.0M−$11.0M
Tax rate (%)——0.0%0.0%0.0%0.0%0.0%
Net Profit−$9.0M−$10.0M−$19.0M−$8.0M−$8.0M−$8.0M−$13.0M
EPS−$1.71−$37.96−$33.17−$3.25−$20.14−$8.36−$3.12

Quarterly Results — Last 12 Quarters (USD millions)

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Sep '26
Revenue$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M—$1.0M$1.0M——
Operating Expenses$3.0M———————————
Operating Profit−$3.0M———————————
Operating Margin-281.0%———————————
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax−$3.0M−$1.0M−$2.0M−$2.0M−$2.0M−$3.0M−$2.0M−$2.0M−$2.0M−$2.0M−$3.0M−$2.0M
Tax rate (%)0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net Profit−$3.0M−$1.0M−$2.0M−$5.0M−$2.0M−$3.0M−$2.0M−$6.0M−$2.0M−$2.0M−$3.0M−$2.0M
EPS−$15.24−$3.71−$3.58−$3.66−$2.71−$3.64−$1.94−$0.43−$0.44−$0.51−$0.73−$0.42

Over the 8 years reported for Mentari Therapeutics, Inc., cash stood at $11.0M in the latest year, shareholders' equity was $130.0M, current assets covered current liabilities 1.50 times.

Balance Sheet — 8 Years (USD millions)

Metric20192020202120222023202420252026
Total Assets—$8.0M$10.0M$13.0M$14.0M$12.0M$16.0M$3.0M
Current Assets—$6.0M$8.0M$10.0M$11.0M$9.0M$13.0M$3.0M
Cash$10.0M$6.0M$7.0M$6.0M$9.0M$7.0M$11.0M$11.0M
Inventory———$2.0M$2.0M$1.0M$1.0M$1.0M
Receivables—$0$0$0$0$0$0$0
Fixed Assets—$0$0$1.0M$1.0M$1.0M$1.0M$0
Capital Work in Progress$0$0$0$0$0$0$0$0
Investments—$0$0$0$0$0$0$0
Other Assets—$1.0M$0$0$0$0$0$0
Total Liabilities—$2.0M$2.0M$4.0M$2.0M$3.0M$2.0M$2.0M
Current Liabilities—$2.0M$2.0M$3.0M$2.0M$2.0M$2.0M$2.0M
Other Liabilities—$2.0M$2.0M$4.0M$2.0M$3.0M$2.0M$2.0M
Equity—$71.0M$82.0M$102.0M$113.0M$119.0M$127.0M$130.0M
Reserves$14.0M$6.0M$7.0M$9.0M$12.0M$9.0M$13.0M$1.0M

For Mentari Therapeutics, Inc., operating cash flow was positive in 0 of 7 reported years; free cash flow in the latest year was negative at $9.0M; free cash flow was positive in 0 of 7 years.

Cash Flow Statement — 7 Years (USD millions)

Metric2020202120222023202420252026
Operating Cash Flow−$7.0M−$10.0M−$16.0M−$7.0M−$7.0M−$8.0M−$9.0M
Investing Cash Flow$4.0M$0−$1.0M−$1.0M$0——
Financing Cash Flow$0$11.0M$15.0M$11.0M$5.0M$12.0M$0
Net Cash Flow−$4.0M$1.0M−$1.0M$3.0M−$2.0M$4.0M−$9.0M
Free Cash Flow−$7.0M−$10.0M−$16.0M−$7.0M−$7.0M−$8.0M−$9.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-195.51%
Quick Ratio1.00
Interest Coverage—
Return 1Y2.76%
Return 3Y-75.91%
Return 5Y-99.78%

Mentari Therapeutics, Inc. (MTRI) financials — frequently asked questions

What is Mentari Therapeutics, Inc.'s annual revenue?

Mentari Therapeutics, Inc. (MTRI) reported annual revenue of $5.0M in its most recent fiscal year.

What is Mentari Therapeutics, Inc.'s net profit?

Mentari Therapeutics, Inc. (MTRI) reported a net loss of $13.0M in its most recent fiscal year.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Financial Services StocksLow P/E Financial Services StocksHigh Net Margin Financial Services StocksDividend Financial Services StocksLow Debt Financial Services StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
MTRI Overview MTRI Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.